Myongji Hospital
| Republic of Korea | Thailand | Turkey | |
| Targeted therapy | from AUD $7,690 | from AUD $9,787 | from AUD $1,398 |
| Stomach resection | from AUD $25,866 | from AUD $16,778 | from AUD $16,778 |
| Small intestine resection | from AUD $103 | from AUD $11,884 | from AUD $5,354 |
| Resection of gallbladder | from AUD $8,109 | from AUD $4,195 | from AUD $5,663 |
| Laparoscopic Anti-Reflux (GERD) Surgery | from AUD $11,884 | from AUD $11,884 | from AUD $4,894 |
No hidden fees – just official clinic prices. Pay at the clinic for Gastroenterology treatment upon arrival and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Gastroenterology treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Gastroenterology treatment journey.
Professor Kim Jong-yeon is a gastroenterologist at Myongji Hospital. He treats diseases of the esophagus, stomach, colon, and liver, including cirrhosis and hepatitis. He performs therapeutic endoscopy, such as endoscopic polypectomy. He also serves as Deputy Director of the International Healthcare Center.
He is a member of the Liver Failure Center. He works with teams in hepatology, liver cancer, and transplantation to provide coordinated care for advanced liver disease and for transplant candidates.
MD, Jeonbuk National University College of Medicine. Clinical Professor of Gastroenterology at Myongji Hospital. Member of the Korean Association of Internal Medicine, the Korean Society of Gastroenterology, and the Korean Society of Gastrointestinal Endoscopy. Former resident and fellow at Inje University Ilsan Paik Hospital.
Professor Park Jung-won is a leading Korean specialist in hepatocellular carcinoma with over 30 years of experience. He is the Director of the Liver and Liver Cancer Center and the Integrated Cancer Care Center at Myongji Hospital. He led Korea’s first HCC guidelines in 2003. He has also overseen their updates for about 20 years. His team validated proton beam radiotherapy for liver cancer, as published in the Journal of Hepatology. He has authored more than 200 SCI-indexed papers. He also helped lead global trials, including the 2025 CheckMate 9DW study, which showed improved outcomes with nivolumab plus ipilimumab for unresectable HCC.
MD/PhD, Seoul National University; Member, National Academy of Medicine of Korea; former President, Korean Liver Cancer Association; Chair, Korean HCC Guidelines Committee; Prime Minister’s and Health Minister’s commendations; Pfizer Medical Research Award and Roche Oncology Academic Award.